SEC Filing Summary: PerkinElmer, Inc. (10-Q)
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for PerkinElmer, Inc. (Note: The input metadata lists "REVVITY, INC.", but the filing text explicitly identifies the registrant as PerkinElmer, Inc.). The report covers the quarterly period ended September 29, 2002, and the nine-month period ended on the same date. The company operates in four reportable segments: Life Sciences, Optoelectronics, Analytical Instruments, and Fluid Sciences. Significant corporate actions during the period included the adoption of new accounting standards (SFAS No. 142) and the classification of several businesses (Telecom Components, Entertainment Lighting, Security and Detection Systems) as discontinued operations.
Key Financial Metrics
| Metric | Three Months Ended Sep 29, 2002 | Nine Months Ended Sep 29, 2002 | Nine Months Ended Sep 30, 2001 |
|---|---|---|---|
| Sales (Revenue) | $366.0 million | $1,095.4 million | $1,119.4 million |
| Operating Income (Continuing Ops) | $16.7 million | $19.2 million | $155.7 million |
| Net Income (Loss) | $7.1 million | ($149.3 million) | $84.1 million |
| Diluted EPS | $0.06 | ($1.19) | $0.81 |
| Cash and Equivalents | $97.5 million (Sep 29, 2002) | Decreased $40.7 million YTD | |
| Total Debt | $592.0 million (Sep 29, 2002) | Reduced by $132.1 million YTD | |
| Operating Cash Flow | $51.5 million (Nine Months 2002) vs $65.1 million (Nine Months 2001) |
Material Changes vs. Prior Period
- Revenue Decline: Nine-month sales decreased 2% ($24.0 million) compared to the prior year. Organic revenue declined 9% due to industry-wide downturns in Life Sciences, Optoelectronics, and Analytical Instruments markets, offsetting revenue from the Packard acquisition.
- Profitability Collapse: Operating income from continuing operations dropped significantly from $155.7 million in the prior year to $19.2 million. This was driven by lower sales volumes, reduced capacity utilization, and a $17.2 million inventory write-down in the Optoelectronics segment.
- Accounting Change Impact: The adoption of SFAS No. 142 (Goodwill and Other Intangible Assets) resulted in a one-time, non-cash impairment charge of $117.8 million related to the lighting reporting unit. This charge is the primary driver of the reported net loss of $149.3 million for the nine-month period.
- Discontinued Operations: The company recorded losses from discontinued operations, including a $17.5 million pre-tax loss on the disposition of the Telecom Components business and a $10.9 million loss on the disposition of the Security and Detection Systems business (net of tax).
Guidance, Outlook, and Risks
- Liquidity and Debt Refinancing: Management anticipates that cash on hand and operating cash flow will fund operations in the near term. However, the company faces a significant refinancing need within the next 12 months, specifically regarding $404 million in zero-coupon convertible debentures that holders may require the company to repurchase in August 2003.
- Debt Covenants: Credit facilities were amended in September 2002, reducing borrowing capacity under the 364-day facility and adding provisions that further reduce capacity based on asset sales or debt repurchases. A new consolidated indebtedness leverage ratio was added.
- Market Risks: The company faces risks from cyclical downturns in key end-markets (telecom, pharmaceutical, semiconductor), foreign exchange fluctuations (approx. 50% of sales are international), and the potential for further intangible asset impairments under SFAS No. 142.
- Legal Proceedings: The company is defending against a purported class action lawsuit regarding misleading statements about prospects and future results, as well as a patent infringement and breach of contract suit filed by Enzo Biochem, Inc.
Investor Verification Checklist
- Refinancing Plan: Verify the status of the commitment from Merrill Lynch Capital Corporation for a $445 million facility and the issuance of $225 million in senior subordinated debt to address the 2003 debenture maturity.
- Goodwill Impairment: Confirm the methodology and assumptions used for the $117.8 million goodwill impairment charge and assess the risk of future impairments in other reporting units.
- Discontinued Operations: Review the final working capital adjustments for the sale of the Security and Detection Systems business and the timeline for the sale of the Fluid Sciences unit.
- Organic Revenue Trends: Analyze the 9% decline in organic revenue to determine if the downturn in Life Sciences and Optoelectronics is temporary or structural.
- Legal Exposure: Monitor the progress of the class action lawsuit and the Enzo Biochem litigation for potential material financial impact.